BR112012030818A2 - "derivados de ácido c-3 betulínico modificado como inibidores da maturação do hiv" - Google Patents

"derivados de ácido c-3 betulínico modificado como inibidores da maturação do hiv"

Info

Publication number
BR112012030818A2
BR112012030818A2 BR112012030818A BR112012030818A BR112012030818A2 BR 112012030818 A2 BR112012030818 A2 BR 112012030818A2 BR 112012030818 A BR112012030818 A BR 112012030818A BR 112012030818 A BR112012030818 A BR 112012030818A BR 112012030818 A2 BR112012030818 A2 BR 112012030818A2
Authority
BR
Brazil
Prior art keywords
inhibitors
modified
betulinic acid
acid derivatives
hiv maturation
Prior art date
Application number
BR112012030818A
Other languages
English (en)
Inventor
Regueiro-Ren Alicia
Swidorski Jacob
Liu Zheng
A. Meanwell Nicholas
Sit Sing-Yuen
Chen Jie
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of BR112012030818A2 publication Critical patent/BR112012030818A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J63/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008Expansion of ring D by one atom, e.g. D homo steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators

Abstract

derivados de ácido c-3 betulínico modificado inibidores da maturação do hiv. compostos tendo propriedades medicamentosas e que podem afetar biologia, suas composições farmacêuticas e métodos de uso são apresentados. em particular, ácido c-3 betulínico modificado e outros derivados de produtos naturais estruturalmente relacionados que possuem atividade antiviral ímpar são fornecidos como inibidores da maturação do hiv. esses compostos são úteis para o tratamento de hiv e aids.
BR112012030818A 2010-06-04 2011-06-02 "derivados de ácido c-3 betulínico modificado como inibidores da maturação do hiv" BR112012030818A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35133810P 2010-06-04 2010-06-04
PCT/US2011/038879 WO2011153315A1 (en) 2010-06-04 2011-06-02 Modified c-3 betulinic acid derivatives as hiv maturation inhibitors

Publications (1)

Publication Number Publication Date
BR112012030818A2 true BR112012030818A2 (pt) 2019-09-24

Family

ID=44627236

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012030818A BR112012030818A2 (pt) 2010-06-04 2011-06-02 "derivados de ácido c-3 betulínico modificado como inibidores da maturação do hiv"

Country Status (12)

Country Link
US (1) US8754068B2 (pt)
EP (1) EP2576585B8 (pt)
JP (1) JP5752789B2 (pt)
CN (1) CN103038245B (pt)
AR (1) AR081637A1 (pt)
BR (1) BR112012030818A2 (pt)
CA (1) CA2801487C (pt)
EA (1) EA022393B1 (pt)
ES (1) ES2612452T3 (pt)
MX (1) MX2012013703A (pt)
TW (1) TW201201793A (pt)
WO (1) WO2011153315A1 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11090313B2 (en) 2010-05-20 2021-08-17 University Of Iowa Research Foundation Methods for inhibiting muscle atrophy
AU2011255495A1 (en) 2010-05-20 2012-12-06 The United States Of America, As Represented By The Secretary Of The Department Of Veterans Affairs Methods for inhibiting muscle atrophy
KR101886467B1 (ko) * 2011-01-31 2018-08-07 비브 헬스케어 유케이 (넘버4) 리미티드 Hiv 성숙 억제 활성을 갖는 c-17 및 c-3 변형 트리테르페노이드
EP2670764B1 (en) * 2011-01-31 2015-09-02 Bristol-Myers Squibb Company C-28 amines of c-3 modified betulinic acid derivatives as hiv maturation inhibitors
JP6001060B2 (ja) 2011-06-06 2016-10-05 ユニバーシティ オブ アイオワ リサーチ ファウンデーション 筋萎縮を阻害するための方法
AU2012312485B2 (en) 2011-09-21 2016-09-01 VIIV Healthcare UK (No.5) Limited Novel betulinic acid derivatives with antiviral activity
US8906889B2 (en) * 2012-02-15 2014-12-09 Bristol-Myers Squibb Company C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
US8889854B2 (en) 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
WO2014105926A1 (en) 2012-12-31 2014-07-03 Hetero Research Foundation Novel betulinic acid proline derivatives as hiv inhibitors
EP2953960A1 (en) * 2013-02-06 2015-12-16 Bristol-Myers Squibb Company C-19 modified triterpenoids with hiv maturation inhibitory activity
BR112015019590A2 (pt) 2013-02-25 2017-07-18 Bristol Myers Squibb Co derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv
AR101077A1 (es) 2014-04-11 2016-11-23 Bristol Myers Squibb Co Triterpenoides con actividad inhibidora de la maduración de hiv
WO2015195776A1 (en) 2014-06-19 2015-12-23 Bristol-Myers Squibb Company Betulinic acid derivatives with hiv maturation inhibitory activity
US20170129916A1 (en) 2014-06-26 2017-05-11 Hetero Research Foundation Novel betulinic proline imidazole derivatives as hiv inhibitors
KR20170092580A (ko) * 2014-11-14 2017-08-11 비브 헬스케어 유케이 (넘버5) 리미티드 연장된 베툴린산 유사체
CA2967679A1 (en) 2014-11-14 2016-05-19 VIIV Healthcare UK (No.5) Limited Oxolupene derivatives
KR20170092581A (ko) 2014-11-14 2017-08-11 비브 헬스케어 유케이 (넘버5) 리미티드 C17-아릴 치환된 베툴린산 유사체
MA40886B1 (fr) 2015-02-09 2020-03-31 Hetero Research Foundation Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih
WO2016147099A2 (en) 2015-03-16 2016-09-22 Hetero Research Foundation C-3 novel triterpenone with c-28 amide derivatives as hiv inhibitors
CN108026140A (zh) 2015-07-28 2018-05-11 葛兰素史克知识产权第二有限公司 用于预防或治疗hiv感染的白桦脂醇衍生物
BR112018001537A2 (pt) 2015-07-28 2018-09-18 Glaxosmithkline Ip No 2 Ltd composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para tratamento e para prevenção de uma infecção por hiv em um indivíduo, e, uso de um composto ou sal
KR20180054826A (ko) 2015-09-24 2018-05-24 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 Hiv 성숙 억제 활성을 갖는 화합물
CN108699103A (zh) 2016-01-20 2018-10-23 葛兰素史克知识产权第二有限公司 具有hiv成熟抑制活性的羽扇烷类的胺衍生物
AR107512A1 (es) 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
WO2018002848A1 (en) * 2016-06-30 2018-01-04 VIIV Healthcare UK (No.5) Limited Azadecalin derivatives as inhibitors of human immunodeficiency virus replication
WO2018002849A1 (en) * 2016-06-30 2018-01-04 VIIV Healthcare UK (No.5) Limited Triterpenoid inhibitors of human immunodeficiency virus replication
EP3478661A1 (en) * 2016-06-30 2019-05-08 ViiV Healthcare UK (No.5) Limited Aza-substituted inhibitors of human immunodeficiency virus replication
US20210347813A1 (en) 2018-04-24 2021-11-11 Viiv Healthcare Uk (No. 5) Limited Compounds with hiv maturation inhibitory activity
PL237998B1 (pl) 2018-05-28 2021-06-28 Narodowy Inst Lekow Fosfonowe pochodne kwasu 3-karboksyacylobetulinowego, sposób ich otrzymywania oraz ich zastosowanie

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5962527A (en) 1995-03-21 1999-10-05 The Board Of Trustees Of The University Of Illinois Method and composition for treating cancers
US5869535A (en) 1995-03-21 1999-02-09 The Board Of Trustees Of The University Of Illinois Method and composition for selectively inhibiting melanoma
US5679828A (en) * 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
DE69934486T2 (de) 1998-03-02 2007-10-04 The University Of North Carolina At Chapel Hill Office Of Technology Development Acylierte betulin- und dihydrobetulinderivate, ihre herstellung und verwendung
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
JP2006504704A (ja) * 2002-09-26 2006-02-09 パナコス ファーマシューティカルズ, インコーポレイテッド モノアシル化ベツリンおよびジヒドロベツリン誘導体、その製造および使用
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
CN100432094C (zh) * 2003-02-11 2008-11-12 诺瓦利克斯制药公司 抑制肿瘤生长的药物
US20050014730A1 (en) 2003-04-02 2005-01-20 Carlson Robert M. Anti-fungal formulation of triterpene and essential oil
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
RU2387665C2 (ru) 2004-03-17 2010-04-27 Панакос Фармасьютикалз, Инк. Фармацевтические соли 3-о-(3', 3'-диметилсукцинил)бетулиновой кислоты
US20060019934A1 (en) * 2004-05-20 2006-01-26 Saxena Brij B Anti-HIV-1 activity of betulinol derivatives
TW200628161A (en) * 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
WO2007098247A2 (en) * 2006-02-21 2007-08-30 Achillion Pharmaceuticals, Inc. Substituted taraxastanes useful for treating viral infections
WO2008127364A2 (en) 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
US20090105203A1 (en) * 2006-10-16 2009-04-23 Myriad Genetics, Incorporated Compounds for treating viral infections
WO2009020732A1 (en) * 2007-08-03 2009-02-12 Advanced Life Sciences, Inc. Lupane-type triterpenoids modified at 30-position and analogues thereof
WO2009042166A1 (en) 2007-09-25 2009-04-02 Panacos Pharmaceuticals, Inc. Liquid bevirimat dosage forms for oral administration
WO2009100532A1 (en) 2008-02-14 2009-08-20 Virochem Pharma Inc. NOVEL 17ß LUPANE DERIVATIVES
WO2009114083A2 (en) 2008-03-03 2009-09-17 Panacos Pharmaceuticals, Inc. Determinants of antiviral response
BRPI0911422B8 (pt) * 2008-04-18 2021-05-25 Reata Pharmaceuticals Inc compostos moduladores inflamatórios antioxidantes, composição farmacêutica e usos dos mesmos
MX2012009319A (es) * 2010-02-11 2012-09-12 Glaxosmithkline Llc Derivados de betulina.

Also Published As

Publication number Publication date
JP2013527242A (ja) 2013-06-27
EP2576585B1 (en) 2016-10-12
US20120142707A1 (en) 2012-06-07
ES2612452T3 (es) 2017-05-17
EP2576585A1 (en) 2013-04-10
EP2576585B8 (en) 2016-12-21
EA201270780A1 (ru) 2013-04-30
CN103038245B (zh) 2015-03-25
CA2801487C (en) 2017-12-05
US8754068B2 (en) 2014-06-17
MX2012013703A (es) 2012-12-17
JP5752789B2 (ja) 2015-07-22
CA2801487A1 (en) 2011-12-08
TW201201793A (en) 2012-01-16
CN103038245A (zh) 2013-04-10
WO2011153315A1 (en) 2011-12-08
EA022393B1 (ru) 2015-12-30
AR081637A1 (es) 2012-10-10

Similar Documents

Publication Publication Date Title
BR112012030818A2 (pt) "derivados de ácido c-3 betulínico modificado como inibidores da maturação do hiv"
BR112012030810A2 (pt) "c-28 amidas de derivados de ácido c-3 betulínico modificados como inibidores de maturação de hiv"
EA201391127A1 (ru) C-17 и c-3 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
BR112015019590A2 (pt) derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv
UY31673A1 (es) "derivados heterocíclicos de urea y métodos de uso de los mismos-211"
MX2013004491A (es) Boronatos como inhibidores de arginasa.
ECSP14006132A (es) Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih
EA201170249A1 (ru) 3,4-диарилпиразолы в качестве ингибиторов протеинкиназ
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
BR112014010105A2 (pt) aminas de c-28 de derivados de ácido betulínico modificado por c-3 como inibidores de maturação de hiv
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
GT201200321A (es) Derivados de heteroaril imidazolona como inhibidores de jak
UY31305A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmacéuticas que las contienen.
DOP2011000107A (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), produccion y uso de los mismos como productos medicinales
BR112014001665A2 (pt) compostos de 2,3-di-hidroimidazo[1,2-c]pirimidin-5(1h)-ona utilizados como inibidores de lp-plaz
CL2015000039A1 (es) Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis.
UY31864A (es) Derivados de urea hetericíclica y métodos de uso de los mismos-332
HN2011002578A (es) Nuevos derivados de compuestos de [3,2-c]pirazol esteroidal con actividad clucocorticoide.
CY1122596T1 (el) Νεες φαρμακοτεχνικες μορφες (τριμεθοξυφαινυλαμινο)πυριμιδινυλιου
JOP20170029B1 (ar) C-3 وc-17 تراي تربينويد معدلة كمثبطات لـhiv-1
DOP2006000257A (es) Derivados de 9-cloro-15-desoxiprostaglandina, procesos para su preparación y su uso como medicamento
BR112017009850A2 (pt) composto, composição, e, uso de uma quantidade melhoradora de hiv de um composto
UY32154A (es) Derivados de isoquinolinona, procesos para su preparacion, composiciones farmaceuticas que los contiene y su uso en terapia
PH12018501640A1 (en) C-3 and c-17 modified triterpenoids as hiv-1 inhibitors
BR112017009852A2 (pt) composto, composição, e, usos de um composto

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.